{"id":806032,"date":"2026-04-30T20:23:01","date_gmt":"2026-04-30T20:23:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=806032"},"modified":"2026-04-30T20:23:01","modified_gmt":"2026-04-30T20:23:01","slug":"preeclampsia-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/preeclampsia-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight_806032.html","title":{"rendered":"Pre-Eclampsia Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777552966.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pre-Eclampsia Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777552966.jpg\" alt=\"Pre-Eclampsia Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Pre-Eclampsia Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pre-Eclampsia pipeline landscape. It covers the Pre-Eclampsia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pre-Eclampsia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Curious about the latest updates in the Pre-Eclampsia Pipeline? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pre-eclampsia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Pre-Eclampsia Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Pre-Eclampsia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Pre-Eclampsia Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pre-Eclampsia treatment.<\/li>\n<li>The leading Pre-Eclampsia Companies such as <strong><em>Evergreen Therapeutics Inc., Comanche Biopharma <\/em><\/strong>and others.<\/li>\n<li>Promising Pre-Eclampsia Therapies such as <strong><em>Antithrombin gamma, physiological saline, Coenzyme Q10, Nifedipine, Labetalol, Methyldopa, Oral misoprostol, Oxytocin<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Want to know which companies are leading innovation in Pre-Eclampsia? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pre-eclampsia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Pre-Eclampsia Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Pre-Eclampsia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Pre-Eclampsia Pipeline Report also highlights the unmet needs with respect to the Pre-Eclampsia.<\/p>\n<p style=\"text-align: justify;\"><strong>Pre-Eclampsia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Preeclampsia is a pregnancy-specific hypertensive disorder that usually develops after 20 weeks of gestation and is characterized by new-onset high blood pressure, often accompanied by proteinuria or signs of organ dysfunction. It is part of a spectrum of hypertensive disorders in pregnancy and can progress to severe conditions such as eclampsia or HELLP syndrome if not properly managed. Affecting approximately 2&ndash;8% of pregnancies worldwide, preeclampsia is a major cause of maternal and perinatal morbidity and mortality. Early diagnosis and appropriate management are essential to reduce the risk of complications for both the mother and the fetus.<\/p>\n<p style=\"text-align: justify;\"><strong>Pre-Eclampsia Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>EG-101: Evergreen Therapeutics, Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">EG-101 is an investigational, AI-enabled, small-molecule drug candidate from Evergreen Therapeutics designed to treat preeclampsia. It has received FDA Investigational New Drug (IND) clearance for Phase I trials. EG-101 aims to treat preeclampsia by reducing hypertension and proteinuria, addressing a major unmet need in pregnancy care. In preclinical models, EG-101 demonstrated efficacy in ameliorating hypertension and proteinuria. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Pre-Eclampsia.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>CBP-4888: Comanche Biopharma<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated small interfering ribonucleic acid (siRNAs) duplex oligonucleotides (siRNA-2283 and siRNA-2519) targeting two soluble fms-like tyrosine kinase&ndash;1 (sFLT1) mRNA isoforms. In August 2023, the company have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Pre-Eclampsia.<\/p>\n<p style=\"text-align: justify;\"><strong>If you&rsquo;re tracking ongoing Pre-Eclampsia Clinical trials, this press release is a must-read @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pre-eclampsia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Pre-Eclampsia Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Pre-Eclampsia Pipeline report provides insights into:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Pre-Eclampsia with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pre-Eclampsia Treatment.<\/li>\n<li>Pre-Eclampsia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Pre-Eclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pre-Eclampsia market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Pre-Eclampsia Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Evergreen Therapeutics Inc., Comanche Biopharma <\/em><\/strong>and others<strong><em>.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pre-Eclampsia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Pre-Eclampsia Products have been categorized under various Molecule types such as,<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>From emerging drug candidates to competitive intelligence, the Pre-Eclampsia Pipeline Report covers it all &ndash; check it out now @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pre-eclampsia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Pre-Eclampsia Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Pre-Eclampsia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Pre-Eclampsia Companies- <strong><em>Evergreen Therapeutics Inc., Comanche Biopharma <\/em><\/strong>and others.<\/li>\n<li>Promising Pre-Eclampsia Therapies- <strong><em>Antithrombin gamma, physiological saline, Coenzyme Q10, Nifedipine, Labetalol, Methyldopa, Oral misoprostol, Oxytocin<\/em><\/strong>, and others.<\/li>\n<li>Pre-Eclampsia Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Pre-Eclampsia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay ahead in Healthcare Research &ndash; discover what&rsquo;s next for the Pre-Eclampsia Treatment landscape in this detailed analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pre-eclampsia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Pre-Eclampsia Emerging Drugs and Major Players<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Pre-Eclampsia: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Pre-Eclampsia&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Drug name: Company name<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Drug name: Company name<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>CBP-4888: Comanche Biopharma<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>CB-CHMF-11: Corion Biotech<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Inactive Products<\/li>\n<li>Pre-Eclampsia Key Companies<\/li>\n<li>Pre-Eclampsia Key Products<\/li>\n<li>Pre-Eclampsia- Unmet Needs<\/li>\n<li>Pre-Eclampsia- Market Drivers and Barriers<\/li>\n<li>Pre-Eclampsia- Future Perspectives and Conclusion<\/li>\n<li>Pre-Eclampsia Analyst Views<\/li>\n<li>Pre-Eclampsia Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=preeclampsia-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pre-eclampsia-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/pre-eclampsia-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=preeclampsia-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Pre-Eclampsia Pipeline Insight 2026&rdquo; report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pre-Eclampsia pipeline landscape. It covers the Pre-Eclampsia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pre-Eclampsia Pipeline Therapeutics &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/preeclampsia-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight_806032.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-806032","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=806032"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806032\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=806032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=806032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=806032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}